Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | HPD | P32754 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837660 | 0.81 | HPD (0.47) | HPDALDH1A1SMN1; SMN2KDM4EBRD4 | |
| SCHEMBL25139664 | 0.81 | HPD (0.52) | MAPK14HPDALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL6054729 | 0.78 | MAPK14 (0.47) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL13322666 | 0.77 | MAPK14 (0.59) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL30049030 | 0.76 | SLC22A12 (0.57) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL24812336 | 0.76 | HPD (0.55) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL24815336 | 0.76 | SLC22A12 (0.57) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL25139613 | 0.75 | HPD (0.54) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL30048876 | 0.73 | HPD (0.52) | MAPK14HPDALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL24815337 | 0.73 | HPD (0.52) | MAPK14HPDALDH1A1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153985-A1 | Methods of treating acute inflammation in animals with p38 map kinase inhibitors | KEHRLI MARCUS E JR (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153985-A1 | Methods of treating acute inflammation in animals with p38 map kinase inhibitors | MAPK1, MAPKAPK2, MAP3K2 | MAPK14 37/4885HPD 3336/4885ALDH1A1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.